Kamada Ltd (KMDA) posted record nine-month revenue of $152.2 million and lifted its 2026 outlook to $205-$208 million, with management projecting another year of double-digit growth in 2027.
While the top- and bottom-line numbers for Kamada (KMDA) give a sense of how the business performed in the quarter ended September 2026, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
In a new SEC filing on September 29, it was unveiled that Botzer, Board Member at Kamada (NASDAQ:KMDA), acquired stock options for 60,000 shares. What Happened: In a recent Form 4 filing with the U.S. Securities and
In a recent SEC filing, it was disclosed that Ishay Davidi, Board Member at Kamada (NASDAQ:KMDA), made a noteworthy acquisition of company stock options on September 29,. What Happened: Davidi, Board Member at Kamada,
A substantial insider move unfolded on September 29, as Topilsky, Director at Kamada (NASDAQ:KMDA), reported the acquisition of stock options for 86,500 shares in an SEC filing. What Happened: A Form 4 filing from the
A notable acquisition unfolded on September 29, as Botzer, Board Member at Kamada (NASDAQ:KMDA), reported the acquisition of stock options for 60,000 shares in an SEC filing. What Happened: A Form 4 filing from the U.S.
A notable acquisition unfolded on September 29, as Davidi, Board Member at Kamada (NASDAQ:KMDA), reported the acquisition of stock options for 86,500 shares in an SEC filing. What Happened: Davidi, Board Member at
Disclosed in a recent SEC filing, Lilach Asher Topilsky, Director at Kamada (NASDAQ:KMDA), made a strategic move by acquiring company stock options on September 29,. What Happened: Disclosed in a Form 4 filing on
Kamada (NASDAQ:KMDA) outlined its growth strategy, product portfolio and financial outlook during a company presentation, emphasizing demand for specialty plasma-derived therapies and a plan to expand through product sales, distribution agreements, plasma supply and potential acquisitions. The comp
A noteworthy insider acquisition was disclosed on September 24, as Payorski, Director at Kamada (NASDAQ:KMDA), reported the acquisition of stock options for 60,000 shares. What Happened: Payorski, Director at Kamada,
A significant insider transaction involving the exercise of company stock options was reported on September 24, by Boris Gorelik, VP at Kamada (NASDAQ:KMDA), as per the latest SEC filing. What Happened: Disclosed in a
A substantial insider move unfolded on September 25, as London, Chief Executive Officer at Kamada (NASDAQ:KMDA), reported the acquisition of stock options for 800,000 shares in an SEC filing. What Happened: In a Form 4
Disclosed in a recent SEC filing, David Tsur, Board Member at Kamada (NASDAQ:KMDA), made a strategic move by acquiring company stock options on September 23,. What Happened: Revealed in a Form 4 filing on Wednesday with
A noteworthy insider acquisition was disclosed on September 23, as Nir, VP at Kamada (NASDAQ:KMDA), reported the acquisition of stock options for 112,500 shares. What Happened: Disclosed in a Form 4 filing on Wednesday
A substantial insider move unfolded on September 23, as Itshayek, Director at Kamada (NASDAQ:KMDA), reported the acquisition of stock options for 46,000 shares in an SEC filing. What Happened: In a recent Form 4 filing
Hanni Neheman, VP at Kamada (NASDAQ:KMDA), reported acquisition of company stock options on September 23, according to a new SEC filing. What Happened: In a Form 4 filing with the U.S. Securities and Exchange Commission
A noteworthy insider acquisition was disclosed on September 23, as Dekel, Board Member at Kamada (NASDAQ:KMDA), reported the acquisition of stock options for 46,000 shares. What Happened: In a recent Form 4 filing with
Chaime Orlev, Chief Financial Officer at Kamada (NASDAQ:KMDA), reported acquisition of company stock options on September 23, according to a new SEC filing. What Happened: A Form 4 filing from the U.S. Securities and
In a new SEC filing on September 23, it was unveiled that Livneh, VP at Kamada (NASDAQ:KMDA), acquired stock options for 89,485 shares. What Happened: A Form 4 filing from the U.S. Securities and Exchange Commission on
A substantial acquisition of company stock options by Leon Recanati, Board Member at Kamada (NASDAQ:KMDA) was reported on September 23, based on a new SEC filing. What Happened: Disclosed in a Form 4 filing on Wednesday
In a recent SEC filing, it was disclosed that Karnit Goldwasser, Board Member at Kamada (NASDAQ:KMDA), made a noteworthy acquisition of company stock options on September 24,. What Happened: In a Form 4 filing with the
In a new SEC filing on September 23, it was unveiled that Tsur, Director at Kamada (NASDAQ:KMDA), acquired stock options for 37,500 shares. What Happened: Revealed in a Form 4 filing on Wednesday with the U.S.
Detailed price information for Kamada Ltd (KMDA-Q) from The Globe and Mail including charting and trades.
Complete stats, fight record, and career highlights for Yusuke Kamada. Latest news, upcoming fights, and detailed MMA history at MMA Junkie.
Detailed price information for Kamada Ltd (KMDA-Q) from The Globe and Mail including charting and trades.
U.S. Centers for Disease Control and Prevention (CDC) Reports a Significant Year-Over-Year Increase in Nationwide Rabies Exposures and Rabies Immunoglobulin Utilization KedRAB is One of Only Two FDA-Approved Anti-Rabies Immunoglobulin Products in the U.S. Market Estimated at $200 Million AnnuallyKamada’s Manufacturing Capacity and Supply Availability Positioned to Support Increased Demand REHOVOT, Israel, and HOBOKEN, N.J., Sept. 17, 2026 (GLOBE NEWSWIRE) -- Kamada Ltd. (NASDAQ: KMDA; TASE: KMDA
Detailed price information for Kamada Ltd (KMDA-Q) from The Globe and Mail including charting and trades.
REHOVOT, Israel, and HOBOKEN, N.J., Sept. 10, 2026 (GLOBE NEWSWIRE) -- Kamada Ltd. (NASDAQ: KMDA; TASE: KMDA.TA), a global biopharmaceutical company with a portfolio of marketed products indicated for rare and serious conditions and a leader in the specialty plasma-derived field, today announced that Amir London, Chief Executive Officer, will participate and present at the H.C. Wainwright 28th Annual Global Investment Conference, taking place at the Lotte New York Palace Hotel. Mr. London is sch
REHOVOT, Israel and HOBOKEN, N.J., Sept. 03, 2026 (GLOBE NEWSWIRE) -- Kamada Ltd. (the “Company”) (NASDAQ: KMDA; TASE: KMDA.TA), a global biopharmaceutical company with a portfolio of marketed products indicated for rare and serious conditions and a leader in the specialty plasma-derived field, announced today that it has obtained a tax ruling (the “Ruling”) from the Israel Tax Authority (the “ITA”) with respect to the cash dividend of $0.17 (approximately NIS 0.51) per share on the Company’s or
This is the newest page. Registered accounts read further back.